Archivos por Etiqueta: #CovidVaccines

Vaccination campaign in San Felipe Friday February 19: 200 Americans and Canadians will receive vaccine

san felipe

ALFREDO AZCARATE VARELA
THE BAJA POST/EDITOR

The National Vaccination Campaign has already started all over Mexico, this Friday there will be medical personnel applying the vaccine to senior citizens (over 60 years old) in the Municipal Development (DESOM) Module in San Felipe, only for those people who are older than 60 years old and made an appointment, and this figure includes about 200 Americans and Canadians living in San Felipe.

Sixty thousand people have already made an appointment to receive the first vaccination dose, nevertheless, information is somehow confusing, two days ago the Federal Delegate for Baja California, Alejandro Ruiz Uribe, said that people who didn´t make an appointment could show up at the vaccination points and request to be given the dose of the Pfizer vaccine, which is the one that has been administered since the campaign kicked off early this week.

Baja California Health secretary, Alonso Pérez Rico, has ordered all the staff involved to continue vaccinating and today it´s San Felipe senior residents turn, and said that only those who made appointments will receive the first dose against COVID-19.

Given the contrasting information given by the Federal Delegate and the Health Secretary, the recommendation to all those, older than 60 years old and who didn´t make an appointment, is to try and make one or wait for the next Coronavirus vaccine lot which will be arriving as of next week.

http://www.saludbc.gob.mx

Sputnik V, the Russian vaccine against COVID19, is 91% effective in phase III trial, say scientists

THE BAJA POST
NEWSROOM
https://www.dw.com/en/russias-sputnik-v-covid-vaccine-highly-effective-new-study-shows/a-56416767

The Russian vaccine Gam-COVID-Vac, also known as Sputnik V, is 91.6 % effective against symptomatic COVID-19, a phase III trial has shown. The preliminary results of this crucial final round of testing were published in the prestigious medical journal The Lancet on Tuesday.
The findings are based on data from nearly 20,000 people who participated in the study in 25 hospitals and clinics in Moscow from September through November 202

Researchers at Russia’s Gamaleya National Research Centre for Epidemiology and Microbiology, where Sputnik V was developed, say they are happy with the results. «Our interim analysis of the randomized, controlled, phase III trial of Gam-COVID-Vac in Russia has shown high efficacy, immunogenicity and a good tolerability profile in participants aged 18 years or older,» says Gamaleya’s Dr. Inna V Dolzhikova, co-lead author of the study published in The Lancet. The researchers found no serious negative consequences of vaccination. Reported side effects included flu-like symptoms and pain at the injection site.

Sputnik V was the first coronavirus vaccine to be released worldwide. Russia’s move to start using it on a mass scale last year, before all the trials were completed and results analyzed, has been criticized by the international community. Another point of contention: The Gamaleya research center did not just develop the vaccine but was also in charge of authorizing its use in Russia. In the EU or the US, authorization is handled not by the companies who develop the serum, but by separate entities like the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA).

The release of the phase III results is likely to increase confidence in the Russian vaccine.
«The development of the Sputnik V vaccine has been criticized for unseemly haste, corner-cutting and an absence of transparency. But the outcome reported here is clear and the scientific principle of vaccination is demonstrated,» Professor Ian Jones, University of Reading, and Professor Polly Roy, London School of Hygiene & Tropical Medicine, who were not involved in the study, wrote in a comment about the new findings.

Good results with the elderly as well: The most recent Sputnik V trial included 2,144 participants over 60 years of age, and the vaccine efficacy in this group was 91.8 %. A British coronavirus vaccine developed by AstraZeneca had been criticized for not testing a sufficient number of people from this risk group.